Obexelimab

Obexelimab is Zenas BioPharma's bifunctional anti-CD19 antibody, originally Xencor's XmAb5871, designed to shut down B cells without killing them. The drug binds CD19 with one arm and engages FcγRIIb - the inhibitory brake receptor on B cells - with its Fc tail, forcing B cells and antibody-producing plasmablasts into a switched-off state that reverses when dosing stops. Four programs are running in parallel: Phase 2 MoonStone in relapsing multiple sclerosis [6], Phase 3 in IgG4-related disease [7], Phase 3 SApHiAre in warm autoimmune hemolytic anemia [8], and Phase 2 in systemic lupus [9]. The commercial thesis is differentiation from CD20-depleting antibodies like ocrelizumab and Kesimpta - comparable B-cell suppression, faster reversibility, no depletion-driven hypogammaglobulinemia. The real near-term value driver is IgG4-RD, where there is no approved therapy and Zenas owns the only Phase 3 program. MS is the moonshot - a much bigger market where the efficacy bar set by CD20 depleters is punishing.

Novel compound, never approved anywhere. Originally developed by Xencor as XmAb5871 and licensed to Zenas BioPharma, which IPO'd in September 2024 with obexelimab as the lead asset [10]. Four registrational and registration-enabling trials are active. MoonStone (NCT06564311) is the Phase 2 in relapsing MS, n=93, active not recruiting, with cumulative new gadolinium-enhancing T1 lesions on MRI as the primary endpoint [6]. The IgG4-RD Phase 3 (NCT05662241) is the lead program - n=194, active not recruiting, with full protocol published in Rheumatology and Therapy in early 2026 [3,7]. SApHiAre in warm autoimmune hemolytic anemia (NCT05786573) is Phase 3, n=134, active not recruiting [8]. The SLE Phase 2 (NCT06559163) is recruiting toward n=190 [9]. No FDA breakthrough or fast track designations have been disclosed. IgG4-RD likely qualifies for orphan consideration given that the only options today are glucocorticoids and off-label rituximab. The nearest catalyst is the IgG4-RD Phase 3 readout, expected 2026-2027 based on enrollment status. MS Phase 2 should follow on a similar timeline.

B cells produce antibodies, and in autoimmune disease they produce antibodies that attack your own tissue. The dominant clinical strategy for shutting B cells down is to kill them outright - rituximab, ocrelizumab, and Kesimpta all bind CD20 on B cells and recruit immune cells to destroy them. That works, but it takes months for B cells to repopulate, the drugs do not touch plasmablasts (the antibody-secreting cells, which have shed CD20), and chronic depletion erodes protective antibody levels over time. Obexelimab takes a different route. It binds CD19 - a surface protein present on B cells and plasmablasts - with its variable region, and engages FcγRIIb with its Fc tail. FcγRIIb is the only inhibitory Fc receptor B cells express; it is the built-in brake that normally limits B-cell activation when immune complexes bind. By crosslinking CD19 to FcγRIIb on the same cell, obexelimab forces the brake on. B cells stop signaling, plasmablasts stop secreting, and when dosing stops, B cells come back online quickly [4,5]. The mechanism rests on solid genetics - loss-of-function variants in FCGR2B are associated with SLE in humans, and Fcgr2b knockout mice spontaneously develop lupus-like disease. The drug class is unprecedented in approvals, so the regulatory path has no template. The biology is real; whether the clinical effect size matches CD20 depletion is the open question.

MoonStone (NCT06564311) is the MS Phase 2 - n=93 patients with relapsing MS, primary endpoint is cumulative number of new gadolinium-enhancing T1 lesions on MRI over the treatment period [6]. That is a validated, fast-reading surrogate that lets you see drug effect within months instead of waiting on clinical relapses. The IgG4-RD Phase 3 (NCT05662241) is larger and more important - n=194, with the published protocol in Rheumatology and Therapy 2026 describing a randomized placebo-controlled design with a primary endpoint built around flare-free disease control on a steroid taper [3,7]. SApHiAre in warm AIHA (NCT05786573) is Phase 3, n=134, with a safety/dose run-in followed by efficacy assessment [8]. The SLE Phase 2 (NCT06559163) is recruiting toward n=190 [9]. The prior Phase 2 SLE study showed measurable response in patients selected by gene-expression patterns [2], and the current SLE study presumably incorporates that learning. Trial designs are reasonable across the board - placebo-controlled, with endpoints the FDA accepts in each indication. The MS Phase 2 sample size is modest for a heavily competitive market, but it is sized for MRI-endpoint proof-of-concept, not registration.

About 5 in 100 drugs at this stage in this area ultimately reach approval - that's the starting point. The model then looks at ten specific facts about this trial and its sponsor to adjust that estimate. In this case, several factors pull the number down: the trial uses heavier-than-usual blinding, the sponsor has a thin or weak approval record, earlier-phase results were weak or limited, and the study uses a randomized design. The other factors are close to average for this stage, so the final estimate lands at 5%.

Efficacy risk in MS is the dominant concern. CD20 depletion is the gold standard for B-cell-mediated MS therapy, and the question is whether reversible B-cell silencing produces enough MRI lesion suppression to compete. If MoonStone shows 50% lesion reduction, that is a problem - the depleter class shows 90%+. Safety risk runs the other direction. B-cell inhibition still raises infection rates and can drive hypogammaglobulinemia with chronic dosing, even without depletion. The receptor occupancy and PK work in healthy volunteers and RA patients showed expected biology [4,5], but long-term safety in chronic autoimmune use is the gap. Execution risk: Zenas is a young company that IPO'd in September 2024 with obexelimab as the only material clinical asset [10]. They are running four parallel late-stage programs on essentially one molecule. If IgG4-RD fails, the fallback is thin. Commercial risk in MS is severe: ocrelizumab generated roughly $7.7B for Roche in 2024 and Kesimpta is approaching $3B for Novartis [11,12]. Payers will not pay premium pricing on a 'non-depleting' pitch unless safety differentiation is concrete. In IgG4-RD and warm AIHA, commercial risk is lower because there is no approved competition, but the markets are smaller. The portfolio strategy works only if at least two indications hit.

Watch this. The IgG4-RD Phase 3 is the make-or-break readout - clean regulatory path, no approved competitor, the Phase 2 pilot showed clear clinical benefit [1], and the mechanism fits the disease biology (plasmablasts drive IgG4-RD, and CD19 inhibition shuts plasmablasts down where rituximab cannot). Positive Phase 3 data would establish obexelimab as a registered drug with a defined mechanism, opening the door to the larger indications. The MoonStone MS Phase 2 readout will be informative either way: a strong MRI suppression signal repositions Zenas against the CD20 depleters; a weak signal effectively retires the MS program. SApHiAre in warm AIHA is the third independent shot on goal in a small but underserved indication. Check back when the IgG4-RD Phase 3 reads out - that is the trial that determines whether Zenas is a single-drug biotech that worked or one that did not. Until then, a credible Phase 3 story trading on a real but unproven mechanism, with the key risk being concentration in one molecule across four indications run by a freshly public company.